$26.45
+0.87
(+3.4%)▲
Insights on Avidity Biosciences Inc
Revenue is down for the last 2 quarters, 2.81M → 2.19M (in $), with an average decrease of 22.2% per quarter
Netprofit is down for the last 3 quarters, -47.02M → -60.44M (in $), with an average decrease of 13.4% per quarter
1.4%
Downside
Day's Volatility :4.26%
Upside
2.9%
81.74%
Downside
52 Weeks Volatility :82.54%
Upside
4.37%
Period | Avidity Biosciences Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 127.23% | -1.1% | 0.0% |
6 Months | 399.06% | 10.5% | 0.0% |
1 Year | 128.41% | 5.4% | 0.5% |
3 Years | 18.03% | 14.4% | -21.1% |
Market Capitalization | 1.9B |
Book Value | $6.32 |
Earnings Per Share (EPS) | -2.91 |
PEG Ratio | 0.0 |
Wall Street Target Price | 46.71 |
Profit Margin | 0.0% |
Operating Margin TTM | -3043.46% |
Return On Assets TTM | -23.24% |
Return On Equity TTM | -39.34% |
Revenue TTM | 9.6M |
Revenue Per Share TTM | 0.13 |
Quarterly Revenue Growth YOY | -20.8% |
Gross Profit TTM | -141.2M |
EBITDA | -233.5M |
Diluted Eps TTM | -2.91 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.2 |
EPS Estimate Next Year | -3.53 |
EPS Estimate Current Quarter | -0.66 |
EPS Estimate Next Quarter | -0.83 |
What analysts predicted
Upside of 76.6%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 379.0K | ↓ 97.1% |
Net Income | -11.9M | - |
Net Profit Margin | -3.1K% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 2.3M | ↑ 511.87% |
Net Income | -32.1M | ↑ 169.16% |
Net Profit Margin | -1.4K% | ↑ 1763.69% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 6.8M | ↑ 192.67% |
Net Income | -44.0M | ↑ 36.93% |
Net Profit Margin | -648.03% | ↑ 737.09% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 9.3M | ↑ 37.41% |
Net Income | -117.4M | ↑ 166.86% |
Net Profit Margin | -1.3K% | ↓ 610.49% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 9.2M | ↓ 1.09% |
Net Income | -169.1M | ↑ 44.05% |
Net Profit Margin | -1.8K% | ↓ 574.49% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 9.6M | ↑ 3.64% |
Net Income | -212.2M | ↑ 25.52% |
Net Profit Margin | -2.2K% | ↓ 386.86% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.5M | ↑ 13.96% |
Net Income | -42.3M | ↓ 4.95% |
Net Profit Margin | -1.7K% | ↑ 338.76% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.8M | ↑ 11.56% |
Net Income | -47.7M | ↑ 12.89% |
Net Profit Margin | -1.7K% | ↓ 20.24% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.2M | ↓ 19.36% |
Net Income | -47.2M | ↓ 1.1% |
Net Profit Margin | -2.1K% | ↓ 390.13% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.3M | ↑ 3.72% |
Net Income | -47.0M | ↓ 0.35% |
Net Profit Margin | -2.0K% | ↑ 82.95% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.8M | ↑ 21.68% |
Net Income | -52.4M | ↑ 11.34% |
Net Profit Margin | -1.9K% | ↑ 172.46% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.2M | ↓ 22.18% |
Net Income | -60.4M | ↑ 15.44% |
Net Profit Margin | -2.8K% | ↓ 898.2% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 4.0M | ↓ 96.82% |
Total Liabilities | 45.1M | ↑ 18.7% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 96.9M | ↑ 2333.63% |
Total Liabilities | 162.3M | ↑ 259.7% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 333.9M | ↑ 244.56% |
Total Liabilities | 27.7M | ↓ 82.94% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 427.6M | ↑ 28.06% |
Total Liabilities | 46.2M | ↑ 66.76% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 638.8M | ↑ 49.4% |
Total Liabilities | 60.7M | ↑ 31.58% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 628.6M | ↓ 1.6% |
Total Liabilities | 127.8M | ↑ 110.44% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 430.5M | ↑ 2.31% |
Total Liabilities | 53.6M | ↑ 15.3% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 638.8M | ↑ 48.37% |
Total Liabilities | 60.7M | ↑ 13.38% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 614.0M | ↓ 3.89% |
Total Liabilities | 55.1M | ↓ 9.33% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 610.8M | ↓ 0.52% |
Total Liabilities | 51.6M | ↓ 6.27% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 573.2M | ↓ 6.16% |
Total Liabilities | 55.7M | ↑ 7.92% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 628.6M | ↑ 9.66% |
Total Liabilities | 127.8M | ↑ 129.45% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -9.7M | - |
Investing Cash Flow | -49.0K | - |
Financing Cash Flow | 5.1M | ↓ 94.16% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.5M | ↓ 125.79% |
Investing Cash Flow | -235.0K | ↑ 379.59% |
Financing Cash Flow | 89.2M | ↑ 1634.7% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -37.1M | ↓ 1590.64% |
Investing Cash Flow | -7.8M | ↑ 3212.77% |
Financing Cash Flow | 272.0M | ↑ 204.86% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -94.8M | ↑ 155.44% |
Investing Cash Flow | -82.5M | ↑ 959.95% |
Financing Cash Flow | 176.3M | ↓ 35.19% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -136.3M | ↑ 43.72% |
Investing Cash Flow | -190.0M | ↑ 130.2% |
Financing Cash Flow | 346.2M | ↑ 96.34% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -32.0M | ↓ 10.09% |
Investing Cash Flow | 10.9M | ↓ 161.96% |
Financing Cash Flow | 39.6M | ↑ 2.16% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -39.2M | ↑ 22.62% |
Investing Cash Flow | -7.8M | ↓ 171.06% |
Financing Cash Flow | 243.7M | ↑ 514.98% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -49.0M | ↑ 24.95% |
Investing Cash Flow | 46.0M | ↓ 692.8% |
Financing Cash Flow | 23.0M | ↓ 90.58% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -49.8M | ↑ 1.72% |
Investing Cash Flow | 46.0M | ↑ 0.0% |
Financing Cash Flow | 39.0M | ↑ 69.73% |
Sell
Neutral
Buy
Avidity Biosciences Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Avidity Biosciences Inc | 7.39% | 399.06% | 128.41% | 18.03% | 18.03% |
Moderna, Inc. | 21.5% | 73.44% | -8.79% | -23.24% | 361.25% |
Regeneron Pharmaceuticals, Inc. | 1.52% | 14.97% | 25.57% | 98.37% | 178.01% |
Novo Nordisk A/s | -2.23% | 21.74% | 50.76% | 232.25% | 415.39% |
Vertex Pharmaceuticals Incorporated | -1.37% | 3.97% | 15.22% | 87.53% | 129.5% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Avidity Biosciences Inc | NA | NA | 0.0 | -3.2 | -0.39 | -0.23 | NA | 6.32 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Avidity Biosciences Inc | Buy | $1.9B | 18.03% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 361.25% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 178.01% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 415.39% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 129.5% | 28.81 | 36.68% |
FMR Inc
T. Rowe Price Associates, Inc.
RTW INVESTMENTS, LLC
BlackRock Inc
COWEN AND COMPANY, LLC
Vanguard Group Inc
Avidity Biosciences Inc’s price-to-earnings ratio stands at None
Read Moreavidity biosciences is pioneering a new class of precision medicines – antibody-sirna conjugates (asc™) – to deliver nucleic acid therapeutics against genetic drivers of disease. our ascs have drug-like properties similar to antibodies and antibody-drug conjugates. importantly, their unique sirna-based “payloads” permit selective targeting of disease-associated mrnas against virtually any target of interest. our leadership includes seasoned scientists and executives with deep expertise in the fields of antibody conjugation, chemistry, formulations, oligonucleotide therapeutics, drug delivery and cancer biology. our employees are high energy, creative people who are passionate about solving hard problems and bringing new drugs to patients. we strive to work with partners to discover best-in-class molecules with the goal of long-term, joint value creation. we have also attracted support from top-tier investors including f-prime capital, ecor1 capital, brace pharma and other sophisticated
Organization | Avidity Biosciences Inc |
Employees | 253 |
CEO | Dr. Troy Edward Wilson J.D., Ph.D. |
Industry | Health Technology |
Royalty Pharma Plc
$26.45
+3.4%
Grupo Aeroportuario Del Sureste, Sabdecv
$26.45
+3.4%
Roku, Inc.
$26.45
+3.4%
Stag Industrial, Inc.
$26.45
+3.4%
Janus Henderson Group Plc
$26.45
+3.4%
Crane Nxt Co
$26.45
+3.4%
Construction Partners Inc-a
$26.45
+3.4%
Plains Gp Holdings, L.p.
$26.45
+3.4%
Vanguard Ultra Short Bond Et
$26.45
+3.4%